Modulation of cisplatin cytotoxic activity against leiomyosarcoma cells by epigallocatechin-3-gallate. Issue 11 (3rd June 2018)

• Record Type: Journal Article
• Authors: Dhima, Irida Th.; Peschos, Dimitrios; Simos, Yannis V.; Gkiouli, Maria I.; Palatianou, Maria E.; Ragos, Vasilios N.; Kalfakakou, Vasiliki; Evangelou, Angelos M.; Karkabounas, Spyridon Ch.
• Is Part Of: Natural product research. Volume 32:Issue 11(2018)
• Page Start: 1337
• Page End: 1342
• Publication Date: 2018-06-03
• Subjects: Cisplatin -- epigallocatechin-3-gallate -- cytotoxicity -- apoptosis -- mitochondria -- cell cycle arrest; Natural products -- Periodicals; Natural products -- Research -- Periodicals; Biological Factors -- Periodicals; Biological Products -- Periodicals; 547
• DOI: 10.1080/14786419.2017.1343318
• Languages: English
• ISSNs: 1478-6419

Abstract

Abstract: The aim of this study was to investigate the cytotoxic effect cisplatin in combination with epigallocatechin-3-gallate (EGCG) on leiomyosarcoma cells (LMS cells) in order to identify a less toxic but equally effective alternative. Assays for cell proliferation, colony formation efficiency, induction of apoptosis and cell cycle arrest were performed using the IC50 of cisplatin (8.6 μΜ) as a reference value and a concentration of EGCG (30 μΜ) that caused a non-significant reduction in cell proliferation. Pre-treatment of cells with EGCG for 24 h before the addition of cisplatin increased cytotoxicity up to 8.5% ( p < 0.05) and the number of apoptotic cells by 40%. Epigallocatechin-3-gallate failed to alter S-phase cell cycle arrest induced by cisplatin and to modulate cisplatin effects on mitochondrial function. These results indicate that pre-treatment with EGCG could be used as an adjunctive therapy to maximise effectiveness of chemotherapy. Abstract :